3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
4
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
40
Colonic Neoplasms
10
Neoplasms
8
Stomach Neoplasms
7
Neoplasm Metastasis
5
Carcinoma, Non-Small-Cell Lung
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Gastrointestinal Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Hepatocellular
3
Unresectable Metastatic Colorectal Cancer
2
Liver Neoplasms
2
Gastrointestinal Diseases
2
Gallbladder Neoplasms
2
Digestive System Neoplasms
2
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Recurrence, Local
1
Melanoma
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Disease Progression
1
Interventions
Gemcitabine
27
Cisplatin
24
pembrolizumab
15
durvalumab
12
Fluorouracil
11
Capecitabine
10
Oxaliplatin
9
Leucovorin
8
Bevacizumab
6
Carboplatin
5
Paclitaxel
4
Nivolumab
4
Irinotecan
4
Injections
4
zanidatamab
3
trametinib
3
lenvatinib
3
derazantinib
3
atezolizumab
3
Ramucirumab
3
Docetaxel
3
tremelimumab
2
surufatinib
2
pertuzumab
2
gemcitabine-oxaliplatin regimen
2
envafolimab
2
Trastuzumab
2
S 1 (combination)
2
Itraconazole
2
Cetuximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Biliary Tract Neoplasms
×
Folfox protocol
×
Clear all
NCT07265674
2026-05-14
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3
Recruiting
480 enrolled